- $2.44m
- $2.42m
- 18
- 63
- 49
- 39
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | -1.83 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | 248.21% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 15.13 | 12.84 | 14.39 | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
IMAC Holdings, Inc. is a clinical research and commercialization company. The Company is focused on innovative medical advancements and care in the oncology, neurological, and orthopedic medical specialties. The Company is focused on providing natural, non-opioid solutions to pain as consumers demand conservative treatments for an aging population. Its Investigational New Drug division conducted a clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson’s disease. The Company is also engaged in providing the precision medicine business. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDTs are utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- May 23rd, 2018
- Public Since
- February 13th, 2019
- No. of Shareholders
- 36
- No. of Employees
- 2
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 1,148,321
- Address
- 1605 Westgate Cir, BRENTWOOD, 37027
- Web
- https://imacregeneration.com/
- Phone
- Contact
- Kim Golodetz
- Auditors
- Salberg & Company, P.A.
Upcoming Events for BACK
Q2 2024 IMAC Holdings Inc Earnings Release
Q3 2024 IMAC Holdings Inc Earnings Release
Similar to BACK
23andMe Holding Co.
NASDAQ Capital Market
ADVANCED BIOMED
NASDAQ Capital Market
Akanda
NASDAQ Capital Market
Assure Holdings
NASDAQ Capital Market
Astrana Health
NASDAQ Capital Market
FAQ
What is the Imac Holdings share price?
As of Today at 21:17 UTC, shares in Imac Holdings are trading at $2.49. This share price information is delayed by 15 minutes.
How has the Imac Holdings share price performed this year?
Shares in Imac Holdings last closed at $2.49 and the price had moved by -32.02% over the past 365 days. In terms of relative price strength the Imac Holdings share price has underperformed the S&P500 Index by -45.91% over the past year.
What are the analyst and broker recommendations for Imac Holdings?
The overall consensus recommendation for Imac Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Imac Holdings dividend yield?
Imac Holdings does not currently pay a dividend.
Does Imac Holdings pay a dividend?
Imac Holdings does not currently pay a dividend.
When does Imac Holdings next pay dividends?
Imac Holdings does not currently pay a dividend.
How do I buy Imac Holdings shares?
To buy shares in Imac Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Imac Holdings?
As of the previous close price of $2.49, shares in Imac Holdings had a market capitalisation of $2.86m.
Where are Imac Holdings shares listed?
Here are the trading details for Imac Holdings:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BACK
What kind of share is Imac Holdings?
Based on an overall assessment of its quality, value and momentum Imac Holdings is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Imac Holdings share price forecast for 2024?
The analyst consensus target price for shares in Imac Holdings is $8.25. That is 231.33% above the last closing price of $2.49.
Analysts covering Imac Holdings currently have a consensus Earnings Per Share (EPS) forecast of -$2.53 for the next financial year.
What is the trend in the Imac Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Imac Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -10.1%.
As of the last closing price of $2.49, shares in Imac Holdings were trading +10.18% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Imac Holdings PE Ratio?
The Imac Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.49.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Imac Holdings?
We do not have data on Imac Holdings' directors